[EN] Background Mutations and deregulations in components of the Hedgehog (Hh) pathway have been associated with cancer onset and tumor growth in different malignancies, but their role in non-small cell lung cancer (NSCLC) ...
[EN] Lung cancer is a malignant disease with high mortality and poor prognosis, frequently diagnosed at advanced stages. Nowadays, immense progress in treatment has been achieved. However, the present scenario continues ...
Usó Marco, Marta(Universitat Politècnica de València, 2015-06-05)
[EN] Lung cancer is the leading cause of cancer-related death worldwide, and is the third most common cancer type; it can be classified into two subgroups based on histology: non-small-cell lung cancer (NSCLC) and small-cell ...
[EN] Background: The human gut harbors around 10(13)-10(14) microorganisms, collectively referred to as gut microbiota. Recent studies have found that the gut microbiota may have an impact on the interaction between immune ...
[EN] The prognosis of non-small cell lung cancer (NSCLC) remains poor and heterogeneous and new biomarkers are needed. As the immune system plays a pivotal role in cancer, the study of immune-related markers may provide ...
Gallach García, Sandra(Universitat Politècnica de València, 2017-11-03)
Lung cancer is the leading cause of death cancer-related worldwide, and is the third most common cancer type. The non-small cell lung cancer (NSCLC) comprises almost 85% of all lung cancers and the 5-year survival rate ...
Iranzo González-Cruz, Vega(Universitat Politècnica de València, 2013-07-29)
El cáncer de pulmón es uno de los principales problemas de salud del mundo;
es una enfermedad frecuente, grave y con incidencia en aumento. A estas
características, se añade la complejidad de su tratamiento ...
[EN] Despite the success of immunotherapies in lung cancer, development of new biomarkers for patient selection is urgently needed. This study aims to explore minimally invasive approaches to characterize circulating T ...
Torres Martínez, Susana(Universitat Politècnica de València, 2024-04-22)
[ES] En esta tesis, buscamos profundizar en el estudio del microambiente inmunitario del tumor (TME), lo que resultaría en una mejor caracterización del contexto inmunológico de los pacientes y la búsqueda de nuevos ...
Duréndez Sáez, María Elena(Universitat Politècnica de València, 2024-03-31)
[ES] A pesar de los nuevos avances en el tratamiento del cáncer de pulmón, su tasa de incidencia y mortalidad siguen en cabeza en todo mundo. Concretamente, el cáncer de pulmón no microcítico (CPNM) representa casi el 85% ...
[EN] Background: The average five-year survival for non-small cell lung cancer (NSCLC) patients is approximately 15%. Emerging evidence indicates that microRNAs (miRNAs) constitute a new class of gene regulators in humans ...
[EN] PurposeAfter surgical resection, an ample prognosis variability among stages is observed. Multiple prognostic factors are individually studied and some CRC classifiers have been proposed. Not one have been implemented ...
Moreno Manuel, Andrea(Universitat Politècnica de València, 2025-04-22)
[ES] El cáncer de pulmón no microcítico (CPNM) representa un 80% de los casos de cáncer de pulmón, siendo uno de los tipos de cáncer más frecuentes y mortales. El tratamiento con inmunoterapia ha mejorado significativamente ...
[EN] Introduction: The discovery of driver mutations in non-small cell lung cancer (NSCLC) has led to the development of genome-based personalized medicine. Fifteen to 20% of adenocarcinomas harbor an epidermal growth ...
[EN] BACKGROUND: Liquid biopsy offers a minimally invasive alternative to tissue-based evaluation of mutational status in cancer. The goal of the present study was to evaluate the aggregate performance of OncoBEAM RAS ...
Herreros Pomares, Alejandro(Universitat Politècnica de València, 2020-02-17)
[ES] El cáncer de pulmón es el tipo de cáncer más frecuentemente diagnosticado y la principal causa de muerte debida a cáncer en el mundo, con sólo un 15% de pacientes con una supervivencia mayor a 5 años tras el diagnóstico. ...